How BBL Filler Removal Is Planned: Product Type, Tissue Assessment and Technique-Specific Considerations

Where planning begins after the consultation

Our article on what happens at a BBL filler removal consultation explains how filler history, examination and imaging are gathered. Planning starts when those findings are brought together into a working category. In practice, most situations fall into one of four groups: hyaluronic acid filler that is known or strongly suspected; a non-hyaluronic acid product; an unknown or mixed history; or any of these complicated by infection or significant inflammation.

The category matters because it changes which techniques are reasonable. A plan built for hyaluronic acid would be inappropriate for a permanent synthetic gel, and an aesthetic plan should not proceed while an infection is untreated. When the category is uncertain, the plan should be cautious and explain what additional information might help.

Why product type changes the technique

Fillers used in the buttocks differ chemically. Hyaluronic acid is a substance the body can break down, and cross-linked hyaluronic acid fillers can usually be degraded by a prescription-only dissolving enzyme. Biostimulators and permanent synthetic products behave differently: they are not dissolved by that enzyme and may become incorporated into surrounding tissue.

Published management algorithms for large-volume permanent gluteal fillers and case series on polyacrylamide-type filler complications show how different these pathways can be. They frequently involve surgical teams and imaging beyond ultrasound, and the outcome is often improvement rather than complete removal.

A response to a trial of dissolving treatment does not prove what was injected. Hyaluronic acid can coexist with other materials, and swelling changes after treatment can be misleading. For this reason, an apparent response is interpreted together with history and imaging rather than in isolation.

Turning a scan into a treatment map

When ultrasound is used, it can help show where filler collections sit, how deep they are, whether they are discrete pockets or spread through the tissue, and how they relate to fat, fascia and muscle. Ultrasound evaluation of cosmetic fillers describes characteristic patterns that may suggest particular product types, although appearances can overlap.

For planning, the scan findings are translated into a map on the skin: which collections are targeted, at what depth and in what order. Repeat scanning between sessions can show what has changed. Ultrasound has limits. It depends on the operator and the equipment, may not show every deposit and cannot always confirm the material.

Product within or beneath muscle needs a different conversation

Filler located deep in the gluteal region lies nearer to major vessels and nerves, and our buttock anatomy article explains why tissue plane matters. Deep or intramuscular deposits may need more limited targets, further imaging such as MRI, or referral, rather than the same approach used for superficial collections.

Technique-specific considerations for hyaluronic acid

When hyaluronic acid filler is identified, the dissolving enzyme is injected into the targeted product, often with ultrasound guidance so that treatment is directed at the collection rather than spread through surrounding tissue. Consensus documents, including a guideline on the safe use of the dissolving enzyme in aesthetic medicine, discuss allergy history, dosing principles and follow-up. Some protocols include skin testing before treatment.

The amount treated in one appointment is a planning decision. Large volumes are commonly reduced in stages so that the response, any inflammation and the remaining contour can be reassessed. Staging can also help avoid removing more than intended. Changes may be visible within a day or two, but swelling from the treatment itself can affect the early appearance.

The enzyme is not completely selective for injected filler and can temporarily affect the body’s own hyaluronic acid in surrounding tissue. This is generally regarded as temporary, but it is one reason why targeted placement and appropriate amounts matter. Allergic reactions, swelling, bruising and pain at injection sites are possible.

When the product cannot be dissolved

For non-hyaluronic acid fillers, planning usually begins with whether treatment is needed at all. A stable, painless deposit causing a modest contour change may be monitored. Symptomatic nodules, inflammation, migration or significant deformity require a different discussion.

Where a permanent gel forms liquid collections, drainage or aspiration may sometimes reduce volume. Where product is firm or incorporated into tissue, surgical removal may be considered by an appropriate surgical team, with risks including scarring, contour defects, bleeding, infection and incomplete removal. In these situations, the role of our clinic may be assessment, imaging coordination and referral rather than treatment.

Patients should be told clearly when a material cannot be dissolved. Repeated dissolving injections into a non-hyaluronic acid product would add risk without benefit.

When infection or inflammation changes the order

An infected or acutely inflamed filler area is a medical problem first. Management may include antibiotics, drainage, imaging and, where needed, urgent hospital assessment. Elective contour correction is usually postponed until the infection has been treated and the tissue has settled. Consensus recommendations on late-onset reactions after hyaluronic acid fillers discuss why the timing and type of reaction influence the treatment sequence.

Inflammation that is not infection can still change the plan. Some reactions are managed medically before any removal is attempted, because treating an actively inflamed area may make assessment harder and increase discomfort.

Planning for the contour after removal

Reducing filler can reveal what lies underneath: natural asymmetry, loose skin, dents from previous procedures or tissue irregularities caused by the filler itself. A plan should discuss these possibilities before treatment, so that the outcome is judged against realistic expectations rather than the pre-filler appearance.

Any later contour treatment, including further hyaluronic acid filler, is a separate decision. It is normally considered only once residual product, inflammation and the settled shape have been reassessed. Our page on non-surgical BBL (DBL™) and the article on local anaesthesia and DBL™ describe what is discussed if re-contouring is ever considered.

Filler removal cannot guarantee complete removal, symmetry or a return to a previous appearance. Further sessions, observation or referral may be needed, consistent with GMC guidance on discussing limitations and alternatives.

Frequently asked questions

Medical and regulatory sources consulted

• Dr Ducu Clinics — BBL Filler Removal
• Guideline for the safe use of hyaluronidase in aesthetic medicine
• Hyaluronidase for dermal filler complications: applications and dosage recommendations
• Ultrasonographic evaluation of cosmetic fillers: patterns and frequent complications
• Reviewing the Ultrasound Anatomy of the Gluteal Region and the Mapping of Fillers (2025)
• Management of a Large Quantity of Permanent Gluteal Copolyamide Fillers: Literature Review and Algorithm
• Management of AQUAfilling® Filler Application Complications
• Late-onset reactions after hyaluronic acid dermal fillers: consensus recommendations
• Safety and Efficiency of Minimally Invasive Buttock Augmentation: A Review
• JCCP and partner bodies: Buttock augmentation and other body contouring procedures
• GMC: Guidance for doctors who offer cosmetic interventions
• ASA/CAP: Guidance on marketing cosmetic interventions